

# Free Fatty Acid Receptor 1 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/FF4635733421EN.html>

Date: April 2020

Pages: 70

Price: US\$ 3,500.00 (Single User License)

ID: FF4635733421EN

## Abstracts

Free Fatty Acid Receptor 1 - Pipeline Review, H1 2020

### SUMMARY

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) pipeline Target constitutes close to 16 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Free Fatty Acid Receptor 1 - Pipeline Review, H1 2020, outlays comprehensive information on the Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Free fatty acid receptor 1 (FFA1), also known as GPR40, is a class A G-protein coupled receptor that is encoded by the FFAR1 gene. It is strongly expressed in the pancreatic islet cells and to a lesser extent in the brain. This membrane protein binds free fatty acids, acting as a nutrient sensor for regulating energy homeostasis. The molecules developed by companies in Phase III, Phase I and Preclinical stages are 1, 2 and 9 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Cardiovascular, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Infectious Disease, Oncology and Respiratory which include indications Type 2 Diabetes, Diabetes, Acute Lung Injury, Acute Renal Failure (ARF) (Acute Kidney Injury), Chronic Kidney Disease (Chronic Renal Failure), Hepatitis B, Idiopathic Pulmonary Fibrosis, Liver Cancer, Liver Fibrosis, Myocardial Fibrosis, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH) and Obesity.

Furthermore, this report also reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)

The report reviews Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics and enlists all their major and minor projects

The report assesses Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Free Fatty Acid Receptor 1

(G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) -  
Overview

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) -  
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) -  
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) -  
Companies Involved in Therapeutics Development

Amgen Inc

Cadila Healthcare Ltd

Caldan Therapeutics Ltd

Hyundai Pharma Co Ltd

Ildong Pharmaceutical Co Ltd

Johnson & Johnson

Liminal BioSciences Inc

Merck & Co Inc

Scohia Pharma Inc

Takeda Pharmaceutical Co Ltd

TiumBio Co Ltd

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) -  
Drug Profiles

AM-3189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fasiglifam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOB-047 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDG-16177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-2305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCE-406 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBI-4050 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCO-267 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize FFAR1 and PPARG for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 for Type 2 Diabetes Mellitus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GPR40 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize PPAR Gamma and GPR40 for Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TUG-770 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZYDG-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) -  
Dormant Products

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) -  
Discontinued Products

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) -  
Product Development Milestones

Featured News & Press Releases

Nov 18, 2019: Liminal presents new preclinical data on PBI-4050 and its effect on Angio-  
Proliferative Pulmonary Arterial Hypertension

Nov 12, 2019: Liminal BioSciences presents new preclinical data on PBI-4050

Nov 11, 2019: Liminal Biosciences presents new preclinical data on PBI-4050 at ASN  
Kidney Week 2019

Oct 25, 2019: Liminal BioSciences announces upcoming presentation on its liver  
disease drug candidate PBI-4050 at The Liver Meeting 2019

Oct 24, 2019: Liminal BioSciences announces upcoming presentation on drug  
candidate PBI-4050 at ASN kidney week 2019

Jun 14, 2019: Prometic presents new data on PBI-4050 and its mechanism of action on  
kidney fibrosis at the 56th ERA/EDTA Congress

Jun 11, 2019: Publication regarding a preclinical study of SCO-267, a novel GPR40  
agonist

Jun 05, 2019: SCOHIA PHARMA to present new preclinical data of SCO267, a GPR40 agonist, at The American Diabetes Association's 79th Scientific Sessions

May 22, 2019: Prometic presents new PBI-4050 data on lung fibrosis at the 2019 ATS Conference

Dec 05, 2018: Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alstrom Syndrome

Aug 10, 2018: Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in journal of pharmacology and experimental therapeutics

Aug 07, 2018: Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050

May 22, 2018: Prometic presents new clinical data on PBI-4050 for the treatment of idiopathic pulmonary fibrosis

Apr 12, 2018: Prometic Presents New PBI-4050 Clinical Data From Ongoing Alstrom Syndrome Phase 2 Trial

Mar 28, 2018: Prometic Reports Positive Clinical Data From Ongoing PBI-4050 Phase 2 Study in Alstrom Syndrome Patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Indication, H1 2020  
Number of Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Number of Products under Investigation by Universities/Institutes, H1 2020  
Products under Investigation by Universities/Institutes, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Pipeline by Amgen Inc, H1 2020  
Pipeline by Cadila Healthcare Ltd, H1 2020  
Pipeline by Caldan Therapeutics Ltd, H1 2020  
Pipeline by Hyundai Pharma Co Ltd, H1 2020  
Pipeline by Ildong Pharmaceutical Co Ltd, H1 2020  
Pipeline by Johnson & Johnson, H1 2020  
Pipeline by Liminal BioSciences Inc, H1 2020  
Pipeline by Merck & Co Inc, H1 2020  
Pipeline by Scohia Pharma Inc, H1 2020  
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020  
Pipeline by TiumBio Co Ltd, H1 2020  
Dormant Products, H1 2020  
Dormant Products, H1 2020 (Contd..1), H1 2020  
Discontinued Products, H1 2020



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

### COMPANIES MENTIONED

Amgen Inc

Cadila Healthcare Ltd

Caldan Therapeutics Ltd

Hyundai Pharma Co Ltd

Ildong Pharmaceutical Co Ltd

Johnson & Johnson

Liminal BioSciences Inc

Merck & Co Inc

Scohia Pharma Inc

Takeda Pharmaceutical Co Ltd

TiumBio Co Ltd

## I would like to order

Product name: Free Fatty Acid Receptor 1 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/FF4635733421EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FF4635733421EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970